Nektar Therapeutics (NASDAQ:NKTR – Get Free Report)‘s stock had its “market perform” rating reissued by analysts at William ...

Nektar Therapeutics (NKTR) stock surges as Oppenheimer upgrades ahead of key mid-stage trial readout for an eczema drug. Read ...

Shuttle Pharmaceuticals SHPH stock declined by 25.6% to $0.32 during Friday's pre-market session. The company's market cap stands at $1.5 million. AirSculpt Technologies AIRS shares decreased by 16.33 ...

Q4 2024 Earnings Call Transcript March 12, 2025 Nektar Therapeutics misses on earnings expectations. Reported EPS is $-0.15 ...

Full Year 2024 Results Key Financial Results Revenue: US$98.4m (up 9.2% from ...

Oppenheimer upgraded Nektar (NKTR) to Outperform from Perform with a $6 price target The firm is refreshing its model ahead of the company’s ...

Oppenheimer upgraded Nektar (NKTR) to Outperform from Perform with a $6 price target Light Up your Portfolio with Spark:Easily identify stocks' ...

EDT Nektar (NKTR) up 12% to 91c after Oppenheimer upgrade with $6 targetLight Up your Portfolio with Spark:Easily identify stocks' risks ...

In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Nektar Therapeutics (NKTR – Research Report), with a ...

Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the fourth quarter ended December 31, 2024. Cash ...

William Blair analyst Andy Hsieh reiterated a Hold rating on Nektar Therapeutics (NKTR – Research Report) today. The company’s shares closed ...

Despite a net loss, Nektar Therapeutics (NKTR) showcases promising developments in its autoimmune pipeline and maintains a ...